Punjab’s hepatitis C strategy is being measured in rupees, cases, and access

A facility-based hepatitis C screening and treatment strategy in Punjab is being evaluated through two lenses that matter to health ministries: what it costs and whether the health system can absorb it. The BMJ Open analysis centers on a question that sits at the intersection of infectious disease control and financing: when people are screened and treated inside health facilities rather than left to navigate fragmented pathways, does the model produce enough clinical value to justify the budget footprint?

Hepatitis C is a chronic viral infection with a long lead time to severe outcomes, and that delay is precisely what makes screening policy so consequential. Patients may appear clinically stable for years while liver injury advances silently. By the time cirrhosis, portal hypertension, or hepatocellular carcinoma becomes obvious, treatment is more complex and the cost to the health system is higher. A facility-based model aims to find infection earlier, connect patients to antiviral therapy faster, and reduce the downstream burden of advanced liver disease.

The paper’s title places Punjab at the center of the analysis, which matters because state-level implementation often determines whether elimination goals remain theoretical or become operational. India’s public health response to hepatitis C depends not only on drug efficacy but also on how efficiently screening, confirmatory testing, counseling, and treatment can be embedded into routine care. A facility-based approach can shorten the time from diagnosis to therapy, but it also concentrates costs upfront in clinics, laboratories, and follow-up services.

One sentence captures the policy tension: early detection is expensive before it becomes cheaper.

Why facility-based screening changes the economics of hepatitis C care

Facility-based screening differs from opportunistic case finding in the community because it places diagnostic work inside existing points of care. That structure can improve linkage to treatment, reduce patient drop-off, and simplify referral chains. It also creates a clearer budget picture for administrators, since the same system that identifies infected patients is responsible for confirmatory testing and treatment initiation.

For hepatitis C, that sequence is clinically important. Screening alone does not alter outcomes unless infected patients complete the diagnostic pathway and receive antiviral therapy. In a system with poor follow-up, the cost of testing can accumulate without yielding meaningful health gains. In a system with reliable linkage, the same screening investment can avert future liver morbidity and avoid costly hospital-based care.

Economic analyses like this one usually matter most when a health system must decide whether to expand coverage, which populations to prioritize, and how fast to scale. In Punjab, those decisions are not abstract. Program planners need to know whether a facility-based model fits within the state budget, whether it is affordable relative to other public health demands, and whether it can be sustained long enough to change prevalence and complication rates.

The clinical logic behind screening before cirrhosis develops

Hepatitis C is especially suited to cost-effectiveness analysis because modern treatment can cure most patients, but the value of cure depends on timing. Treating patients before advanced fibrosis develops prevents future decompensation, transplantation, and cancer surveillance burdens. When therapy is delivered earlier, the benefits compound over years rather than months: less chronic inflammation, less fibrotic progression, and fewer end-stage liver complications.

The facility-based model also fits the reality of many health systems where laboratory infrastructure and prescribing authority are already concentrated in hospitals and clinics. Rather than building an entirely separate outreach network, policymakers can use existing touchpoints to identify infected individuals. The clinical challenge is ensuring that screening capacity is matched by confirmatory diagnostics and a dependable treatment pathway. A program that expands testing without treatment access risks creating delay rather than cure.

Budget impact analysis is especially relevant here because even a highly effective intervention can strain short-term spending. Drug procurement, laboratory assays, staff time, and patient tracing all create visible costs before long-term savings emerge. A state health authority has to decide whether those up-front costs are feasible within annual spending limits and whether the savings from avoided complications will arrive quickly enough to justify expansion.

What this study type can and cannot answer

Cost-effectiveness work is not the same as a therapeutic trial. It does not prove that one antiviral regimen is biologically superior or that one patient group responds better than another. Instead, it translates clinical pathways into economic consequences. That translation is essential for public health, especially in chronic infections where treatment success depends on diagnosis, access, and retention in care as much as on virology.

The title alone signals a policy-facing design rather than a bedside intervention report. It asks whether a health service model can deliver good value within Punjab’s fiscal constraints. It also implies a second layer of analysis: the budget impact of scaling the program. Those two perspectives often pull in different directions. An intervention can be cost-effective over a long horizon and still be difficult to fund immediately if the initial spending spike is large.

The programmatic question for Punjab is straightforward even if the mathematics are not: how much must the system spend now to prevent a larger burden later? In hepatitis C, that burden includes chronic liver disease, advanced fibrosis, cirrhosis-related admissions, and cancer care. Each avoided complication represents not just a clinical gain but a reduction in future health-system pressure.

Policy decisions will hinge on the balance between access and affordability

For state-level hepatitis C control, the practical issue is not whether cure is possible; it is whether cure can be delivered at population scale. Facility-based screening has the appeal of administrative simplicity and clinical continuity. It can also become the backbone of elimination strategies if the funding model supports testing, treatment, and follow-up in the same setting.

The remaining questions are financial and operational. Can Punjab sustain the screening volume needed to find undiagnosed infection? Can treatment start quickly after diagnosis? Can the laboratory and pharmacy supply chain keep pace without creating bottlenecks? Those questions determine whether the model remains a pilot exercise or becomes a durable public health intervention.

For now, the study places economic discipline around a familiar clinical problem. Hepatitis C is treatable, but elimination depends on whether health systems are willing to pay the front-end cost of finding infected patients early and treating them before liver disease becomes irreversible.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by BMJ Open.